Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 4, 2014, Pages 646-655

  Xiao, Wei ^a   Chen, Xiaoyun ^a   Liu, Xialin ^a   Luo, Lixia ^a   Ye, Shaobi ^a   Liu, Yizhi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition (EMT); Histone deacetylase inhibitor; Proliferation; Proliferative vitreoretinopathy (PVR); Retinal pigment epithelium (RPE) cells

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRICHOSTATIN A;

CELL PROLIFERATION; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; PATHOLOGY; PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; VITREORETINOPATHY;

CELL PROLIFERATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MAP KINASE SIGNALING SYSTEM; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84897957021     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12212     Document Type: Article

References (34)

1. Kroll P, Rodrigues EB, Hoerle S. Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica. 2007; 221: 78-94.
2. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest. 2007; 117: 576-86.
3. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002; 21: 127-44.
4. Zheng XZ, Du LF, Wang HP. An immunohistochemical analysis of a rat model of proliferative vitreoretinopathy and a comparison of the expression of TGF-beta and PDGF among the induction methods. Bosn J Basic Med Sci. 2010; 10: 204-9.
5. Cui JZ, Chiu A, Maberley D, et al. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond). 2007; 21: 200-8.
6. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994; 331: 1286-92.
7. Kita T, Hata Y, Arita R, et al. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci USA. 2008; 105: 17504-9.
8. Kita T, Hata Y, Kano K, et al. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes. 2007; 56: 231-8.
9. Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond). 2013; 124: 651-62.
10. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 2005; 25: 1608-19.
11. Henderson C, Mizzau M, Paroni G, et al. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem. 2003; 278: 12579-89.
12. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Molecular oncology. 2012; 6: 579-89.
13. Rombouts K, Niki T, Greenwel P, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res. 2002; 278: 184-97.
14. Niki T, Rombouts K, De Bleser P, et al. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology. 1999; 29: 858-67.
15. Lei W, Zhang K, Pan X, et al. Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition. Int J Biochem Cell Biol. 2010; 42: 1489-97.
16. Yoshikawa M, Hishikawa K, Marumo T, et al. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol. 2007; 18: 58-65.
17. Rishikof DC, Ricupero DA, Liu H, et al. Phenylbutyrate decreases type I collagen production in human lung fibroblasts. J Cell Biochem. 2004; 91: 740-8.
18. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119: 1429-37.
19. Chung EJ, Chun JN, Jung SA, et al. TGF-beta-stimulated aberrant expression of class III beta-tubulin via the ERK signaling pathway in cultured retinal pigment epithelial cells. Biochem Biophys Res Commun. 2011; 415: 367-72.
20. Yao K, Ye PP, Tan J, et al. Involvement of PI3K/Akt pathway in TGF-beta2-mediated epithelial mesenchymal transition in human lens epithelial cells. Ophthalmic Res. 2008; 40: 69-76.
21. Wang Z, Li Y, Kong D, et al. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010; 11: 745-51.
22. Gulappa T, Reddy RS, Suman S, et al. Molecular interplay between cdk4 and p21 dictates G/G cell cycle arrest in prostate cancer cells. Cancer Lett. 2013; 337: 177-83.
23. Gloghini A, Buglio D, Khaskhely NM, et al. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol. 2009; 147: 515-25.
24. Al-Janadi A, Chandana SR, Conley BA. Histone deacetylation: an attractive target for cancer therapy? Drugs R D. 2008; 9: 369-83.
25. Noh H, Oh EY, Seo JY, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009; 297: F729-39.
26. Wu MZ, Tsai YP, Yang MH, et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell. 2011; 43: 811-22.
27. Sahlgren C, Gustafsson MV, Jin S, et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA. 2008; 105: 6392-7.
28. Siemens H, Jackstadt R, Hunten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011; 10: 4256-71.
29. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005; 132: 3151-61.
30. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov. 2012; 11: 790-811.
31. Chen XF, Zhang HJ, Wang HB, et al. Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep. 2012; 39: 3549-56.
32. Aomatsu K, Arao T, Sugioka K, et al. TGF-beta induces sustained upregulation of SNAI1 and SNAI2 through Smad and non-Smad pathways in a human corneal epithelial cell line. Invest Ophthalmol Vis Sci. 2011; 52: 2437-43.
33. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009; 19: 128-39.
34. Leask A. Targeting the jagged/notch pathway: a new treatment for fibrosis? J Cell Commun Signal. 2010; 4: 197-8.